TD Asset Management Inc Has $58.21 Million Holdings in United Therapeutics Corporation $UTHR

TD Asset Management Inc lifted its position in United Therapeutics Corporation (NASDAQ:UTHR) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 138,859 shares of the biotechnology company’s stock after buying an additional 6,581 shares during the quarter. TD Asset Management Inc owned about 0.32% of United Therapeutics worth $58,211,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB lifted its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $44,000. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, True Wealth Design LLC lifted its stake in United Therapeutics by 738.5% in the 3rd quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 96 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the completion of the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at $3,908,078.58. This represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $479.91, for a total transaction of $10,797,975.00. The disclosure for this sale is available in the SEC filing. Insiders sold 407,954 shares of company stock worth $197,601,528 in the last 90 days. 10.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday. TD Cowen lifted their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank Of Canada increased their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday. HC Wainwright lifted their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $533.55.

United Therapeutics Trading Down 5.9%

Shares of UTHR stock opened at $503.60 on Friday. The stock has a market cap of $21.68 billion, a P/E ratio of 18.05, a price-to-earnings-growth ratio of 2.85 and a beta of 0.85. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $537.19. The stock has a 50 day simple moving average of $484.64 and a 200 day simple moving average of $444.51.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the company earned $6.19 EPS. Analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.